INVA (75) GPCR (42) PAHC (68) TYRA (41) ⌘ Pro Terminal →

Eton Pharmaceuticals Inc. (ETON) — RQD Stock Rating Cockpit

$53.67 +3.61% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Eton Pharmaceuticals Inc. (ETON) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $1.53B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ETON)Realized 20D OHLCV Swing Band: ±9.8%

RSI-14 MOMENTUMNEUTRAL RANGE

47.930 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

13.37>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE76% OF RANGE

L: $14$53.67H: $66

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (54% profit margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: CRQD 13 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 20 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 29 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on ETON

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (65)

-0.9% ROIC with 53.5% gross margin and 0.66% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (80)

Altman-Z 13.37 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (55)

20/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like ETON

✓Clean SEC annual filing review with no major hidden accounting time-bombs.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (ETON Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ETON // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +122.51%🛡️ HOLDING TREND SUPPORT

2026-10-30O $53.33H $53.67L $51.89C $53.67VOL 335.7K

RES: $71.01SUP: $50.10SMA50: $56.00SMA200: $35.71

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ETON Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ETON Butterfly Map → + Track ETON →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +104.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ETON today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ETON. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ETON today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ETON)

Health Care Rank #169 of 1016 ⚔️ INVA vs ETON Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ETON vs. INVA, GPCR, PAHC, TYRA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Eton Pharmaceuticals Inc. (ETON) ranks #169 by composite RQD confidence (62/100, grade C) and #303 by equity capitalization ($1.53B). Within this direct 5-issuer industry benchmark cohort, PAHC leads on earnings valuation at 32.7x trailing P/E, while INVA leads on capital efficiency and profitability with 14.7% ROIC and 74.8% gross margin. INVA currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with ETON at 62/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ETON ACTIVE Eton Pharmaceuticals Inc.	C	62/100	—	53.5%	-0.9%	+3.61%	$1.53B	Benchmark Subject
INVA Innoviva Inc.	B	75/100	—	74.8%	14.7%	+0.90%	$1.54B	/inva-vs-eton →
GPCR Structure Therapeutics Inc.	D-	42/100	—	—	-19.5%	+2.14%	$1.56B	/gpcr-vs-eton →
PAHC Phibro Animal Health Corporation (Class A)	C+	68/100	32.7x	30.9%	9.9%	+2.59%	$1.58B	/pahc-vs-eton →
TYRA Tyra Biosciences Inc.	D-	41/100	—	—	-35.0%	-1.24%	$1.48B	/tyra-vs-eton →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001710340

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eton Pharmaceuticals Inc. (ETON) reported GAAP revenue of $80.0M (+104.9% vs. FY2024 revenue of $39.0M , and +152.7% cumulative change since FY2023) , GAAP net income of -$4.6M, operating cash flow of $10.5M, and free cash flow of $10.2M (+980.7% YoY). On the balance sheet, ETON closed FY2025 with $92.1M in total assets against $21.8M in total debt (Altman Z-Score: 13.37, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$80.0M	-$4.6M	$10.5M	$10.2M	$92.1M	$21.8M
FY2024 (FY)	2024-12-31	$39.0M	-$3.8M	$969.0K	$943.0K	$76.1M	$29.8M
FY2023 (FY)	2023-12-31	$31.6M	-$936.0K	$6.8M	$6.8M	—	—

3. ETON Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ETON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Eton Pharmaceuticals Inc. (NASDAQ: ETON) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $53.67 (+3.61% 1D, market cap $1.53B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, ETON ranks #169 in composite RQD confidence.

How does ETON compare to INVA and GPCR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ETON carries a Roarable C (62/100 RQD), trailing P/E of N/A, gross margin of 53.5%, and ROIC of -0.9%. By comparison, INVA (Innoviva Inc.) holds a B grade (75/100 RQD, P/E N/A, ROIC 14.7%, cap $1.54B) and GPCR (Structure Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -19.5%, cap $1.56B). Among the 5-stock peer group, PAHC leads on earnings multiple (32.7x) while INVA leads on capital efficiency (14.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ETON?

Per ETON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001710340), Eton Pharmaceuticals Inc. generated $80.0M in revenue (+104.9% YoY), -$4.6M in net income, and $10.2M in free cash flow against $92.1M in total assets and $21.8M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ETON trading relative to its 50-day, 200-day, and 52-week technical levels?

ETON last traded at $53.67 (+3.61% on volume of 369,485 shares), positioning the stock -4.16% below its 50-day simple moving average ($56.00) and +50.29% above its 200-day simple moving average ($35.71). Across its 52-week range of $14.27 to $66.37, ETON sits at the 75.6% percentile with a 14-day RSI of 47.9 (NEUTRAL RANGE) and an implied next-earnings move of ±9.8% ($48.41 to $58.93).

ETON Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ETON stock right now?

Eton Pharmaceuticals Inc. (ETON) currently earns a Roarable Rating of C (Hold — HOLD) with 62/100 RQD Confidence. Solid 54% profit margin (-1% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.

What is ETON's 12-month price target and RQD AI Jury consensus?

ETON's 12-month base price target is $54.64 (range $42.62 to $69.69), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ETON RQD Cockpit ETON 12M Forecast ETON Earnings & Move ETON Dividends & DRIP ETON Insiders & 13F ETON Whale Options ETON Profit Sankey ETON News & Why